Literature DB >> 28591106

The biology of CML supports second-generation TKIs as frontline treatment.

Carmen Fava1, Giuseppe Saglio1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28591106

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  1 in total

Review 1.  Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.

Authors:  Andreas Hochhaus; Massimo Breccia; Giuseppe Saglio; Valentín García-Gutiérrez; Delphine Réa; Jeroen Janssen; Jane Apperley
Journal:  Leukemia       Date:  2020-05-04       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.